Knowledge for recovering Covid-19 patients Increased risk of arrhythmia Complications, is one of the factors that lead to the need to find Methods to efficiently identify potential sources of arrhythmias in recovered patients. An arrhythmia is a problem with the heart rate or rhythm — in other words, a patient with this condition has a heart that beats too fast or too slowly or in an irregular pattern.
Current arrhythmia mapping procedures require a catheter to navigate the heart and map potential sources of arrhythmia, which proves not only invasive but also time and labor-intensive to initiate.
But San Diego, California-based Vektor Medical is looking to offer an alternative. It announced last week that UC San Diego Health is the first hospital to use its FDA-approved vMap technology to map the heart during cardiac ablation.By ablation, heat or cold therapy Apply through catheter Blocks irregular electrical signals to restore a typical heartbeat.
Vektor Medical claims its vMap technology is non-invasive, fast, and less labor-intensive than current catheter mapping methods. The technology is able to identify potential sources of arrhythmias anywhere in the heart using only data from an electrocardiogram.This non-invasive method identifies sources of stable and unstable arrhythmias in all four cardiac chambers, septal walls and outflow tract. It does not require a catheter and the patient is not exposed to more radiation from prolonged use of fluoroscopy.
“vMap is the first technology designed to identify sources of focal and fibrillating arrhythmias anywhere in the heart within three minutes using only standard 12-lead ECG data,” said Mike Monko, co-founder and CEO of Vektor said in an email.
vMap Atrial fibrillation map.
Vektor hopes its product will reduce surgical time and increase first-time ablation success rates, as its system integrates the mapping process and provides 2D and 3D heat maps of the entire heart.
“The benefit of this approach is that doctors spend less time looking for the source and can quickly locate the target area. In fact, we’ve had users share that vMap can save them hours because they’ll know where to go first ,” Monko declared.
According to the press release, Vektor touts that vMap can map the source of arrhythmias on its own without the need for additional equipment or imaging.However, it noted that, if desired, vMap could complement traditional invasive electroanatomical mapping systems, which may be suitable for planning and procedural settings, according to a Press release.
According to Monko, Vektor has raised $15 million. In November, it closed a SAFE funding round to fund the 2022 launch of vMap in selected cardiovascular centers in the United States.
Monko declined to identify the investors, but said the list included “experts in the fields of cardiology, finance and intellectual property.”
As for Victor’s valuation? He also raised objections there.
“The market will ultimately determine our valuation. So far, investors have been enthusiastic and incredibly supportive of our commercial rollout plans,” added Monko.
Image: Image: hudiemm, Getty Images and Vektor Medical
